{"id":"https://openalex.org/W106883867","doi":null,"title":"Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.","display_name":"Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.","publication_year":2014,"publication_date":"2014-03-01","ids":{"openalex":"https://openalex.org/W106883867","mag":"106883867","pmid":"https://pubmed.ncbi.nlm.nih.gov/24855725"},"language":"en","primary_location":{"id":"pmid:24855725","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24855725","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5058935870","display_name":"Ciara Catherine O'Sullivan","orcid":"https://orcid.org/0000-0001-6069-9800","observed_orcids":["https://orcid.org/0000-0001-6069-9800"]},"institutions":[{"id":"https://openalex.org/I145311948","display_name":"Johns Hopkins University","ror":"https://ror.org/00za53h95","country_code":"US","type":"education","lineage":["https://openalex.org/I145311948"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ciara C O'Sullivan","raw_affiliation_strings":["Johns Hopkins University ("],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Johns Hopkins University (","institution_ids":["https://openalex.org/I145311948"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5004542056","display_name":"Rois\u00edn M. Connolly","orcid":"https://orcid.org/0000-0003-0056-1070","observed_orcids":["https://orcid.org/0000-0003-0056-1070"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roisin M Connolly","raw_affiliation_strings":["National Institutes of Health"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institutes of Health","institution_ids":["https://openalex.org/I1299303238"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.6381,"has_fulltext":false,"cited_by_count":20,"citation_normalized_percentile":{"value":0.83154479,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"28","issue":"3","first_page":"186","last_page":"94, 196"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pertuzumab","display_name":"pertuzumab","score":1.0},{"id":"https://openalex.org/keywords/her2-positive-breast-cancer","display_name":"HER2-positive breast cancer","score":0.9940000176429749},{"id":"https://openalex.org/keywords/trastuzumab-resistance","display_name":"trastuzumab resistance","score":0.875},{"id":"https://openalex.org/keywords/accelerated-approval","display_name":"accelerated approval","score":0.6769999861717224},{"id":"https://openalex.org/keywords/her2-targeted-therapy","display_name":"HER2-targeted therapy","score":0.8429999947547913},{"id":"https://openalex.org/keywords/neoadjuvant-therapy","display_name":"neoadjuvant therapy","score":0.8830000162124634},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9580000042915344},{"id":"https://openalex.org/keywords/fda-drug-approval","display_name":"FDA drug approval","score":0.5120000243186951}],"concepts":[{"id":"https://openalex.org/C2781164504","wikidata":"https://www.wikidata.org/wiki/Q1998021","display_name":"Pertuzumab","level":5,"score":0.9798414707183838},{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.9547357559204102},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8514800667762756},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.7436226010322571},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6670250296592712},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.606082558631897},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.5814182162284851},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.5023176670074463},{"id":"https://openalex.org/C2777863537","wikidata":"https://www.wikidata.org/wiki/Q357896","display_name":"Adjuvant","level":2,"score":0.4698046147823334},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.41240212321281433}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017024","descriptor_name":"Chemotherapy, Adjuvant","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D020360","descriptor_name":"Neoadjuvant Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D058990","descriptor_name":"Molecular Targeted Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:24855725","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24855725","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},{"id":"mag:106883867","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24855725","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W135096470","https://openalex.org/W1964862438","https://openalex.org/W1989078916","https://openalex.org/W2007649418","https://openalex.org/W2014457594","https://openalex.org/W2017832231","https://openalex.org/W2026777422","https://openalex.org/W2033488181","https://openalex.org/W2050674912","https://openalex.org/W2095861620","https://openalex.org/W2101979288","https://openalex.org/W2104239861","https://openalex.org/W2118160561","https://openalex.org/W2120661754","https://openalex.org/W2123591186","https://openalex.org/W2136775492","https://openalex.org/W2139135964","https://openalex.org/W2141393790","https://openalex.org/W2142202354","https://openalex.org/W2146406055","https://openalex.org/W2151425644","https://openalex.org/W2153242757","https://openalex.org/W2161708183","https://openalex.org/W2166199281","https://openalex.org/W2318066535","https://openalex.org/W2318605753"],"related_works":["https://openalex.org/W2766034456","https://openalex.org/W2009624280","https://openalex.org/W2038707667","https://openalex.org/W2321955050","https://openalex.org/W2067395077","https://openalex.org/W2307364414","https://openalex.org/W2197264082","https://openalex.org/W2769397950","https://openalex.org/W2283231482","https://openalex.org/W2092112692"],"abstract_inverted_index":{"The":[0],"addition":[1],"of":[2,61,69,80,112,126,144,165,178],"trastuzumab,":[3],"a":[4,133,149],"monoclonal":[5],"antibody":[6],"to":[7,15,55,146,161,169],"human":[8],"epidermal":[9],"growth":[10],"factor":[11],"receptor":[12],"2":[13],"(HER2),":[14],"standard":[16],"chemotherapy":[17,105],"in":[18,26,29,36,58,63,108,128],"patients":[19,45,62,181],"with":[20,104,148,182],"HER2-positive":[21,114,183],"breast":[22,30,115,184],"cancer":[23,31],"has":[24,76],"resulted":[25],"major":[27],"improvements":[28],"outcomes,":[32],"including":[33],"improved":[34],"survival,":[35],"both":[37],"the":[38,59,64,70,78,87,95,109,129,137,142,153,159,176],"adjuvant":[39,50],"and":[40,53,98,106,167],"metastatic":[41,65,113],"settings.":[42],"However,":[43],"some":[44],"experience":[46],"disease":[47],"relapse":[48],"despite":[49],"trastuzumab-containing":[51],"therapy,":[52,171],"resistance":[54,75,168],"trastuzumab":[56,74,107],"develops":[57],"majority":[60],"setting.":[66],"An":[67],"understanding":[68],"molecular":[71],"mechanisms":[72],"underlying":[73],"aided":[77],"development":[79,143],"novel":[81],"HER2-targeted":[82,170],"therapies.":[83],"In":[84,117],"June":[85],"2012,":[86],"HER2":[88],"dimerization":[89],"inhibitor":[90],"pertuzumab":[91,127,145],"was":[92,122],"approved":[93],"by":[94,136],"US":[96],"Food":[97],"Drug":[99],"Administration":[100],"(FDA)":[101],"for":[102,124,180],"use":[103,125],"first-line":[110],"treatment":[111,179],"cancer.":[116,185],"September":[118],"2013,":[119],"accelerated":[120,154],"approval":[121,155],"granted":[123],"neoadjuvant":[130],"setting,":[131],"representing":[132],"landmark":[134],"decision":[135],"FDA.":[138],"This":[139],"article":[140],"discusses":[141],"date,":[147],"particular":[150],"focus":[151],"on":[152],"decision.":[156],"We":[157],"highlight":[158],"need":[160],"identify":[162],"reliable":[163],"biomarkers":[164],"sensitivity":[166],"which":[172],"would":[173],"make":[174],"possible":[175],"individualization":[177]},"counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":7}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}